November 14-17, 2016
November 14, 2016 - 12:20-13:00
Prof. John Robinson, Department of Chemistry, University of Zürich, will be a Speaker at the Europeptides Congress – November 14-17, 2016 in Berlin. Prof. Robinson’s presentation entitled “ Novel Peptidomimetic Antibiotics Targeting Gram-Negative Bacteria”.
Naturally occuring host-defence peptides with folded hairpin structures provide an excellent starting point for the design of peptidomimetics with novel mechanisms of antimicrobial action against pathogenic Gram-negative bacteria. Of particular interest are hairpin-shaped macrocyclic peptidomimetic antibiotics that target essentual ?-barrel proteins on the bacterial outer menbrane. For example, the peptidomimetic murepavidin (POL7080) is currently being tested in phase-II clinical trials in VAP patients, and holds great promise for the treatment of life-threatening Pseudomonas infections.
November 15, 2016 - 15:00-15:40
Steffen Weinbrenner, Ph.D., Head of Drug Discovery, will be a Speaker at the Europeptides Congress – November 14-17, 2016 in Berlin. Dr. Weinbrenner’s presentation entitled “Translating Macrocyclic and Constrained Peptide Therapeutics into the Clinic”.
The presentation will cover two case studies which both resulted in clinical stage programs for diseases with a great unmet medical need: POL6014, a highly potent and selective macrocyclic inhibitor of human neutrophil elastase (HNE) POL6014, administered by aerosol inhalation, is currently in Phase I clinical, development with focus on Cystic Fibrosis and other rare lung diseases. Polyphor's macrocycle pipeline also includes a novel breakthough antibiotics against Gram-negative bacteria, including a pre-clinical, broad spectrum program as well as the Phase II compound POL7080 for the highly-selective treatment of serious infections caused by Pseudomonas aeruginosa.